These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 15636029

  • 1. Primary octreotide LAR therapy in GH-secreting pituitary adenoma.
    Harinarayan CV.
    J Indian Med Assoc; 2004 May; 102(5):258, 260-1. PubMed ID: 15636029
    [Abstract] [Full Text] [Related]

  • 2. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
    Jallad RS, Musolino NR, Salgado LR, Bronstein MD.
    Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
    [Abstract] [Full Text] [Related]

  • 3. [Current alternative in the pharmacotherapy of acromegaly: the long-acting somatostatin analogue octreotide].
    Laczi F, Magony S, Julesz J.
    Orv Hetil; 2002 May 12; 143(19 Suppl):1062-6. PubMed ID: 12063861
    [Abstract] [Full Text] [Related]

  • 4. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
    Plöckinger U, Quabbe HJ.
    Acta Neurochir (Wien); 2005 May 12; 147(5):485-93; discussion 493. PubMed ID: 15806331
    [Abstract] [Full Text] [Related]

  • 5. Octreotide lar affects the volume of pituitary adenoma in acromegalic patients.
    Bałdys-Waligórska A, Krzentowska-Korek A, Gołkowski F, Sokołowski G, Hubalewska-Dydejczyk A.
    Exp Clin Endocrinol Diabetes; 2011 May 12; 119(5):295-9. PubMed ID: 21264808
    [Abstract] [Full Text] [Related]

  • 6. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial.
    Colao A, Pivonello R, Rosato F, Tita P, De Menis E, Barreca A, Ferrara R, Mainini F, Arosio M, Lombardi G.
    Clin Endocrinol (Oxf); 2006 Mar 12; 64(3):342-51. PubMed ID: 16487447
    [Abstract] [Full Text] [Related]

  • 7. [Experience in treating acromegalic patients with long-acting octreotide].
    Szücs N, Mészáros J, Czirják S, Mondok A, Varga I, Gláz E.
    Orv Hetil; 2002 May 12; 143(19 Suppl):1066-70. PubMed ID: 12063862
    [Abstract] [Full Text] [Related]

  • 8. Growth hormone isoforms in acromegalic patients before and after treatment with octreotide LAR.
    Lima GA, Wu Z, Silva CM, Barbosa FR, Dias JS, Schrank Y, Strasburger CJ, Gadelha MR.
    Growth Horm IGF Res; 2010 Apr 12; 20(2):87-92. PubMed ID: 19884028
    [Abstract] [Full Text] [Related]

  • 9. Octreotide in the management of active acromegaly due to inoperable growth hormone-secreting adenoma.
    Candrina R.
    Recenti Prog Med; 1994 Jan 12; 85(1):13-9. PubMed ID: 8184174
    [Abstract] [Full Text] [Related]

  • 10. Five-year follow-up of a 13-year-old boy with a pituitary adenoma causing gigantism--effect of octreotide therapy.
    Schoof E, Dörr HG, Kiess W, Lüdecke DK, Freitag E, Zindel V, Rascher W, Dötsch J.
    Horm Res; 2004 Jan 12; 61(4):184-9. PubMed ID: 14739526
    [Abstract] [Full Text] [Related]

  • 11. Remarkable Shrinkage of a Growth Hormone (GH)-secreting Macroadenoma Induced by Somatostatin Analogue Administration: A Case Report and Literature Review.
    Kurahashi K, Endo I, Kondo T, Morimoto K, Yoshida S, Kuroda A, Aihara KI, Matsuhisa M, Nakajima K, Mizobuchi Y, Nagahiro S, Abe M, Fukumoto S.
    Intern Med; 2017 Sep 15; 56(18):2455-2461. PubMed ID: 28824054
    [Abstract] [Full Text] [Related]

  • 12. Effect of preoperative use of long-acting octreotide on growth hormone secreting pituitary adenoma and transsphenoidal surgery.
    Yin J, Su CB, Xu ZQ, Yang Y, Ma WB, Tao W, Yang Z, Xia XW.
    Chin Med Sci J; 2005 Mar 15; 20(1):23-6. PubMed ID: 15844307
    [Abstract] [Full Text] [Related]

  • 13. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?
    Jallad RS, Musolino NR, Kodaira S, Cescato VA, Bronstein MD.
    Clin Endocrinol (Oxf); 2007 Aug 15; 67(2):310-5. PubMed ID: 17555503
    [Abstract] [Full Text] [Related]

  • 14. Octreotide represses secretory-burst mass and nonpulsatile secretion but does not restore event frequency or orderly GH secretion in acromegaly.
    Biermasz NR, Pereira AM, Frölich M, Romijn JA, Veldhuis JD, Roelfsema F.
    Am J Physiol Endocrinol Metab; 2004 Jan 15; 286(1):E25-30. PubMed ID: 14506078
    [Abstract] [Full Text] [Related]

  • 15. Pituitary tumor disappearance in a patient with newly diagnosed acromegaly primarily treated with octreotide LAR.
    Resmini E, Murialdo G, Giusti M, Boschetti M, Minuto F, Ferone D.
    J Endocrinol Invest; 2005 Feb 15; 28(2):166-9. PubMed ID: 15887864
    [Abstract] [Full Text] [Related]

  • 16. Acromegaly with normal growth hormone levels: response to Sandostatin-LAR treatment.
    Shimon I, Nass D, Hadani M.
    Pituitary; 2000 May 15; 2(4):289-94. PubMed ID: 11081151
    [Abstract] [Full Text] [Related]

  • 17. Reversible shrinkage of a growth hormone-secreting pituitary adenoma by a long-acting somatostatin analogue, octreotide.
    Barakat S, Melmed S.
    Arch Intern Med; 1989 Jun 15; 149(6):1443-5. PubMed ID: 2730266
    [Abstract] [Full Text] [Related]

  • 18. Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs.
    Matrone C, Pivonello R, Colao A, Cappabianca P, Cavallo LM, Del Basso De Caro ML, Taylor JE, Culler MD, Lombardi G, Di Renzo GF, Annunziato L.
    Neuroendocrinology; 2004 Mar 15; 79(3):142-8. PubMed ID: 15103227
    [Abstract] [Full Text] [Related]

  • 19. Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly.
    Biermasz NR, Pereira AM, Smit JW, Romijn JA, Roelfsema F.
    Growth Horm IGF Res; 2005 Jun 15; 15(3):200-6. PubMed ID: 15935982
    [Abstract] [Full Text] [Related]

  • 20. [Estimation of efficacy of the octreotide LAR administration in the patients with somatotropinoma].
    Waśko R, Bolko P, Kostrzewski J, Horst-Sikorska W, Liebert W, Sowiński J.
    Pol Arch Med Wewn; 2001 Aug 15; 106(2):693-8. PubMed ID: 11926144
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.